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Stellingen behorende bij het proefschri 
EXPLORING NEW WAYS OF MEASURING 
THE ECONOMIC VALUE OF VACCINATION
WITH AN APPLICATION TO THE PREVENTION OF ROTAVIRAL DISEASE
1.  The comparison of cost-of-illness study results on rotavirus disease reveals how 
the disease is managed diff erently across countries in Europe (Chapter 2.1).
2.  QALY measurement of rotavirus disease must be analysed by age and disease-
severity level expressed through medical visits and hospital care (Chapter 2.2).
3.  Simplifi ed models are a helpful tool for a fi rst economic evaluation of new vaccines 
in those countries with scarcity of data (Chapter 2.4).
4.  Impact studies of vaccines may reveal the precision of disease models’ prediction 
and may identify unexpected features about the infection, the disease, and the 
vaccine (Chapter 3).
5.  The standard formula for measuring vaccine effi  cacy/eff ectiveness is not accurate 
as soon as the vaccine aff ects the numerator and the denominator in the equation 
in a diff erent way (Chapter 3).
6.  Improvement in quality of care of hospital management should be included in the 
overall value assessment of rotavirus vaccination (Chapter 4.1).
7.  Retrospective administrative databases show that rotavirus vaccination leads to a 
reduction in absenteeism amongst working mothers (Chapter 4.2).
8.  High disease burden linked to low investment in health care hampers the 
applicability and the interpretation of cost-eff ectiveness analysis in low-income 
countries (Chapter 5).
9.  Optimisation modelling and return on investment analysis are alternatives to cost-
eff ectiveness analysis to assess the economic value of new vaccines in low-income 
countries (Chapter 5).
10.  Vaccination introduced in low-income countries should be embedded into a 
total development plan, including improvement of hygienic conditions, family 
planning, educational development, and work opportunities.
11.  Use of drones can only under specifi c conditions be an effi  cient mode of transport 
of vaccines in remote areas such as urgency of the project, high labour cost, heavy 
transport material.
12.  As the fl ow of master students from the Netherlands who fi nalise their studies in 
Flanders, and the fl ow of doctoral students from Belgium who defend their thesis 
in the Netherlands is equivalent, there is a clear gain for the former.
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